Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Oral cancer, which includes malignancies affecting the lips, tongue, gums, cheeks, and floor of the mouth, represents a ...

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has received an average rating of “Hold” from the twenty-two brokerages that are presently covering the firm, MarketBeat reports. Two ...

Open Water Swim Brings 800+ Swimmers and Volunteers to Dive Into Long Island Sound to Support Cancer Research + 8 Additional ...